Safety and Effectiveness of U-500 Insulin Therapy in Patients with Insulin-Resistant Type 2 Diabetes Mellitus

被引:20
作者
Quinn, Suzanne L. [1 ,3 ]
Lansang, M. Cecilia [1 ,3 ]
Mina, Deanna [2 ]
机构
[1] Univ Florida, Malcom Randall Vet Adm Med Ctr, Div Endocrinol, Gainesville, FL 32608 USA
[2] Univ Florida, Malcom Randall Vet Adm Med Ctr, Dept Pharm, Gainesville, FL 32608 USA
[3] Univ Florida, Coll Med, Gainesville, FL 32608 USA
来源
PHARMACOTHERAPY | 2011年 / 31卷 / 07期
关键词
U-500; insulin; insulin resistance; type 2 diabetes mellitus; REGULAR INSULIN; CLINICAL-EXPERIENCE; EXPOSURE; OBESITY; PHARMACOKINETICS; PREVALENCE;
D O I
10.1592/phco.31.7.695
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To assess the safety and effectiveness of highly concentrated U-500 regular insulin in patients with insulin-resistant type 2 diabetes mellitus who were switched from U-100 insulin. Design. Retrospective cohort study Setting. Outpatient diabetes management clinic. Patients. Twenty-one adults with poorly controlled type 2 diabetes and insulin resistance who were referred to the clinic between July 1, 2007, and June 30, 2008, and whose therapy was changed from large doses of U-100 insulin to U-500 insulin. Measurements and Main Results. Demographic and clinical data were collected through a computerized medical record system. Insulin resistance was defined as a requirement of more than 200 units/day of insulin and more than 100 units/injection. The primary outcome was the change in hemoglobin A(1C) (A1C) after switching from any type of U-100 insulin to stabilization with U-500 highly concentrated regular insulin. Secondary outcomes were the changes in number of daily insulin injections, daily insulin dose, and body weight. With use of U-500 insulin, patients were able to achieve an average reduction in A1C of 1.7% (p<0.001). The mean number of daily injections decreased from 4.3 with U-100 insulin to 2.7 after using U-500 insulin (p<0.001), but changes in body weight after the change in insulin were not statistically significant (279.8 vs 279.2 lbs, p=0.429). No patient discontinued U-500 insulin during the study, and none experienced hypoglycemia severe enough to require the assistance of another individual. Conclusion. In patients with insulin-resistant diabetes who have requirements of more than 200 units/day or 100 units/injection, use of U-500 regular insulin provided the same or better glucose control compared with U-100 insulin, with fewer daily injections and reduced injection volume. Although this drug represents an excellent treatment option, its safe use requires an experienced physician, a motivated and cooperative patient, and a dynamic diabetes management team.
引用
收藏
页码:695 / 702
页数:8
相关论文
共 38 条
[1]  
[Anonymous], 2005, Healthcare Benchmarks Qual Improv, V12, P31
[2]   Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance) [J].
Arioglu, E ;
Andewelt, A ;
Diabo, C ;
Bell, M ;
Taylor, SI ;
Gorden, P .
MEDICINE, 2002, 81 (02) :87-100
[3]   Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients [J].
Ballani, Piya ;
Tran, Michael T. ;
Navar, Maria D. ;
Davidson, Mayer B. .
DIABETES CARE, 2006, 29 (11) :2504-2505
[4]   Metabolic syndrome associated with HIV and highly active antiretroviral therapy [J].
Barbaro, Giuseppe ;
Iacobellis, Gialuca .
CURRENT DIABETES REPORTS, 2009, 9 (01) :37-42
[5]  
Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4
[6]  
BINDER C, 1969, ACTA PHARMACOL TOX, VS 27, P1
[7]   A CHANGE TO 100-UNIT INSULIN DOSAGE WILL REDUCE ERRORS [J].
BLOOM, A ;
KEEN, H ;
WATKINS, PJ .
BRITISH MEDICAL JOURNAL, 1981, 283 (6283) :33-34
[8]  
Cochran E, 2007, DIABETES CARE, V30, P1035
[9]  
Cochran E., 2008, Insulin, V3, P211
[10]   Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is associated with hyperinsulinemia and insulin resistance [J].
Cranmer, M ;
Louie, S ;
Kennedy, RH ;
Kern, PA ;
Fonseca, VA .
TOXICOLOGICAL SCIENCES, 2000, 56 (02) :431-436